Pharmaceutical Company Partners

Since 2004, IPM has negotiated five non-exclusive, royalty-free license agreements and one exclusive worldwide rights agreement from pharmaceutical companies to develop, manufacture and distribute eight antiretroviral (ARV) products as microbicides in developing countries.

These licenses ensure that any new product will be available at little or no cost to women in developing countries where incidence of HIV is especially high.

IPM-licensed ARVs

Compound License Mechanism of action IPM development stage
Dapivirine Janssen Sciences Ireland UC (previously Tibotec) NNRTI: Reverse transcription
  • Clinical: Phase III (dapivirine ring)
  • Phase II- completed    (dapivirine gel)
  • Phase I- ongoing   (dapivirine-darunavir gel)
  • Phase I- completed (dapivirine film)
  • Preclinical (dapivirine-contraceptive ring; dapivirine rectal gel)
DS003 (BMS793) BMS gp120: Cell attachment
  • Preclinical       (DS003 vaginal tablet and vaginal ring)
Maraviroc ViiV Healthcare CCR5: Cell Attachment
  • Clinical: Phase I- ongoing       (maraviroc vaginal and rectal gels)
  • Phase I- completed (maraviroc ring; dapivirine-maraviroc ring)
Tenofovir Gilead NRTI: Reverse transcription 
  • Preclinical*
DS001 (L167), DS004 (L872), DS005 (L882) Merck CCR5: Cell Attachment
  • Early preclinical
DS007 (L-644 peptide) Merck gp41: Cell fusion
  • Early preclinical

* Compound is in different stages of development by other organizations

IPM continually seeks opportunities to work with pharmaceutical companies and other public and private sector research-based organizations and institutions to collaborate on developing promising microbicide and other HIV prevention products.

IPM pharmaceutical partners
Bristol-Myers Squibb
Bristol-Myers Squibb, USA
Gilead Sciences, Inc., USA
Merck & Co., Inc., USA

Janssen R&D Ireland

Janssen Sciences Ireland UC

Viiv Healthcare

Viiv Healthcare